

October 09, 2024

To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001

To,  
The Manager – Listing,  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: GLS

Dear Sirs,

**Sub:- Intimation under Regulation 30 of the SEBI (Listing Obligations & Disclosures Requirements) Regulations, 2015**

We wish to inform you that consequent to acquisition of the Company by Nirma Limited, the Board of Directors of the Company, through Circular Resolution dated October 08, 2024, have granted their approval for the change of name of the Company from "GLENMARK LIFE SCIENCES LIMITED" to "ALIVUS LIFE SCIENCES LIMITED", and subsequent alterations in the Memorandum of Association and Articles of Association of the Company, subject to approval of Shareholders through Postal Ballot and approvals of requisite statutory, regulatory or governmental authorities, as may be required under applicable laws.

The notice of Postal Ballot, seeking shareholder's approval, will be sent to all members of the Company in accordance with the provisions of Section 110 of the Companies Act, 2013 read with Rules framed thereunder and Regulations of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended.

This is for your information and record.

Thanking you.

Yours faithfully,  
**For Glenmark Life Sciences Limited**

**Rudalf Corriea**  
**Company Secretary and Compliance officer**

Glenmark Life Sciences Limited

Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai 400 099, India.

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpath, Solapur - 413 213, India.

T: 91 22 68297979 CIN: L74900PN2011PLC139963 E: complianceofficer@glenmarklifesciences.com W: www.glenmarklifesciences.com